HomeUSAJDRF T1D Fund Appoints Sylvia Tobé as Managing Director

JDRF T1D Fund Appoints Sylvia Tobé as Managing Director


JDRF T1D Fund, a Boston, MA-based venture philanthropy investment fund focused on curing type 1 diabetes (T1D), announced that Sylvia Tobé, PhD had joined as a Managing Director.

Dr. Tobé has a decade of life sciences industry experience and joins from Omega Funds, where she served as a Principal on the investment team. In this role, she will focus on early-stage investments and company creation across a diverse range of therapeutic areas, including neurology, immunology, and rare diseases.

Prior to joining Omega Funds, Dr. Tobé spent seven years at Ra Pharmaceuticals, a peptide drug discovery company focused on rare diseases associated with complement dysregulation. During her tenure at Ra Pharmaceuticals, she was involved in the early development of the company’s discovery platform, as well as developing preclinical and translational models for first-in-human studies of its lead product. Dr. Tobé also provided scientific leadership for multiple discovery programs within the company’s internal pipeline and in collaboration with Merck.

The JDRF T1D Fund is a disease-focused venture philanthropy investment fund that invests in companies developing life-changing solutions to treat, prevent, and cure type 1 diabetes (T1D). Since its launch in 2016, it has invested in more than forty private and public companies with an emphasis on cure-oriented therapies. In nurturing a pipeline of next-generation novel opportunities in T1D, the T1D Fund works in partnership with private capital, including venture capital, public market investors, corporations and foundations. The T1D Fund invests in areas strategically aligned with JDRF and the Helmsley Charitable Trust, the global organizations funding T1D research and working to change the lives of those who affected by T1D.